[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Friendship Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":639},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,51,74,101,128,149,179,205,234,255,276,298,320,349,378,404,431,451,474,496,520,541,571,592,614],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":28,"conditions":29,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100641505","phase-2-yang-et-al-anti-pd-1ctla-4-dual-immunotherapy-for-larc-100641505",false,"NCT07596290","Yang et al. Anti-PD-1\u002FCTLA-4 Dual Immunotherapy for LARC","Efficacy and Safety of Neoadjuvant Short-Course\u002FLong-Course Radiotherapy Combined With Anti-PD-1\u002FCTLA-4 Dual Immunotherapy for Locally Advanced Rectal Cancer: A Prospective, Randomized Controlled Trial (RADICAL Trial)","RADICAL","Inclusion Criteria:\n\n1. Age between 18 and 80 years; ECOG performance status 0-1;\n2. Histopathologically confirmed rectal adenocarcinoma via colonoscopy; pMMR or MSS phenotype;\n3. Rectal MRI stage II\u002FIII (excluding T4b); distal tumor margin ≤ 12 cm from the anal verge;\n4. Willingness to comply with study procedures; consent to use tissue and blood samples for medical research purposes;\n5. No prior history of radiotherapy, chemotherapy, or immunotherapy;\n6. No immune system diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, pemphigus, dermatomyositis, mixed connective tissue disease, hyperthyroidism\u002Fhypothyroidism, ulcerative colitis, autoimmune hemolytic anemia, HIV infection, etc.);\n7. No severe cardiac, pulmonary, hepatic, or renal dysfunction; no jaundice or gastrointestinal obstruction;\n8. No concurrent acute infection;\n9. Baseline laboratory evaluations completed as required, with results obtained within 14 days before randomization, and laboratory values meeting the following criteria (per CTCAE 5.0):\n\n   * White blood cell count ≥ 2000\u002FμL;\n   * Neutrophil count ≥ 1500\u002FμL;\n   * Platelet count ≥ 100×10³\u002FμL;\n   * Hemoglobin ≥ 9.0 g\u002FdL;\n   * Serum creatinine ≤ 1.5×upper limit of normal (ULN) or creatinine clearance \\> 50 mL\u002Fmin (female: creatinine clearance = \\[140 - age (years)\\] × body weight (kg) × 0.85 \u002F (72 × serum creatinine (mg\u002FdL)); male: creatinine clearance = \\[140 - age (years)\\] × body weight (kg) × 1.00 \u002F (72 × serum creatinine (mg\u002FdL)));\n   * AST ≤ 3×ULN, ALT ≤ 3×ULN, total bilirubin ≤ 1.5×ULN;\n10. No psychiatric\u002Fpsychological disorders affecting social function;\n11. Negative serum pregnancy test (blood HCG) within 1 week before randomization for women of childbearing potential;\n12. Women of childbearing potential must agree to use effective contraception during the study period and for 5 months after the last dose of study drug;\n13. Male subjects who are sexually active with women of childbearing potential must agree to use effective contraception during the study period and for 7 months after the last dose of study drug, and must refrain from sperm donation during this period.\n\nExclusion Criteria:\n\n1. Multiple primary cancers or concurrent other malignant tumors;\n2. Patients requiring emergency surgery due to intestinal obstruction, intestinal perforation, gastrointestinal bleeding, etc.;\n3. Factors affecting oral drug absorption (e.g., inability to swallow, nausea\u002Fvomiting, diarrhea, intestinal obstruction, etc.);\n4. Any uncontrolled, severe concomitant diseases;\n5. Hypersensitivity to any component of the study drugs;\n6. Expected survival \\\u003C 5 years for any reason;\n7. Planned or previous organ\u002Fbone marrow transplantation;\n8. Treatment with immunosuppressants or corticosteroids within 1 month before enrollment;\n9. Central nervous system disorders that may impair ability to provide informed consent or comply with study procedures, as determined by the investigator;\n10. Other conditions that may prevent completion of study treatment (e.g., alcoholism, drug addiction, etc.);\n11. Pregnant or breastfeeding women.","ALL","18 Years","80 Years",{"count":22,"type":23},342,"ESTIMATED","INTERVENTIONAL",[26,27],"PHASE2","PHASE3","This is a prospective, multicenter, randomized controlled trial aimed at comparing different radiotherapy fractionation regimens combined with sequential dual immunotherapy versus traditional chemoradiotherapy in neoadjuvant treatment for locally advanced rectal cancer (LARC). A total of 342 pMMR\u002FMSS LARC patients will be enrolled and randomly assigned in a 1:1:1 ratio to short-course radiotherapy (5×5Gy) followed by sequential dual immunotherapy (paromlimab + tuvonralimab + CAPEOX), long-course radiotherapy followed by sequential dual immunotherapy, or conventional long-course chemoradiotherapy. The primary endpoint is the complete response rate (pCR + cCR). Secondary endpoints include the proportion of patients adopting the \"watch-and-wait\" strategy, disease-free survival, overall survival, and safety. This study innovatively explores the synergistic mechanism of different radiotherapy fractionations with dual immunotherapy, optimizes the timing of immunotherapy initiation, and constructs a clinical-imaging-pathology multimodal efficacy prediction model, aiming to advance LARC treatment from empirical to precision therapy while achieving organ and function preservation.",[30,31,32],"Locally Advanced Rectal Adenocarcinoma","Neoadjuvant Chemoradiation","Neoadjuvant Immunotherapy",[34,35,36,37,38],"Locally advanced rectal cancer","Neoadjuvant chemoradiation","Anti-PD-1\u002FCTLA-4 Dual Immunotherapy","Short-course radiotherapy","Long-course rediotherapy","NOT_YET_RECRUITING","2026-06-16",{"date":42,"type":43},"2026-06-17","ACTUAL",{"date":45,"type":23},"2026-07-15",{"date":47,"type":23},"2030-12-31",{"name":49,"class":50},"Beijing Friendship Hospital","OTHER",{"id":52,"slug":4,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100581857","NCT06855758","Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation","Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation, A Double-blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with end-stage renal disease aged 18 years or above\n\nExclusion Criteria:\n\n* simultaneous multiple organ transplantation\n* known allergy to study medication\n* known pregnancy status\n* cancellation of surgery due to grafts or personal reasons\n* persistent severe preoperative hypertension that may not require intraoperative supportive therapy with vasoactive medications\n* any other reason that the supervising physician or the anesthesiologist on duty think the patient is not suitable for the study",{"count":58,"type":23},150,[60],"NA","Prospective double blind randomized controlled trial. By randomizing patients undergoing kidney transplantation into a conventional catecholamine drug (dobutamine) blood pressure maintenance group and a terlipressin-complexed dobutamine group, the investigators compared the effect of intraoperative blood pressure maintenance and the dosage of the vasoactive drug, postoperative graft function, delayed graft function, and other related complications between the two groups, in order to demonstrate whether the use of terlipressin for blood pressure regulation during kidney transplantation is superior to the existing treatments.",[63,64,65],"Kidney Transplant","Delayed Graft Function","Intraoperative Hypotension","RECRUITING",{"date":42,"type":43},{"date":69,"type":43},"2025-03-06",{"date":71,"type":23},"2027-06",{"name":49,"class":50},1,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":100,"locationsCount":73},"100643367","real-world-data-linkage-research-platform-100643367","NCT07635355","Real-World Data Linkage Research Platform","Inclusion Criteria:\n\n* Participants will be eligible for inclusion if they meet all of the following criteria:\n\n  1. Availability of any health-related data generated from routine clinical care, health examinations, or disease surveillance systems, regardless of disease type or health status.\n  2. Presence of at least one type of usable data, including but not limited to diagnostic information (structured or unstructured), laboratory results, imaging data, or basic demographic information.\n  3. Records contain sufficient information (appropriately anonymized) to allow data organization and, where feasible, linkage at the individual level across time points or data sources.\n\nExclusion Criteria:\n\n* Participants or records meeting any of the following criteria will be excluded:\n\n  1. Records lacking minimal essential information required to distinguish individual records or support basic analysis (e.g., completely missing identifiers or time information).\n  2. Records confirmed to be invalid, including system-generated test data, corrupted entries, or records that do not represent real clinical or health-related events.\n  3. Exact duplicate records that cannot be resolved through standard data processing (only one record will be retained when duplicates are identifiable).",true,{"count":82,"type":23},300000,"OBSERVATIONAL","This study aims to address the lack of intelligent governance tools in clinical data management to promote efficient governance and secure sharing of real-world health data. To achieve this, a self-adaptive, automated governance intelligent agent will be developed based on a High-Order Programming (HOP) architecture, integrating Large Language Models (LLMs) and deep learning techniques. The agent will continuously monitor and correct data quality issues in real time, improving data accuracy and usability.\n\nIn parallel, the project will establish a trusted data-sharing framework by integrating AI Confidential Computing (AICC) with Trusted Data Matrix (TDM) technologies. This framework will enable secure, real-time cross-institutional data exchange and collaborative computation while protecting sensitive information.\n\nOverall, the study aims to transform fragmented clinical data into high-quality, standardized, and securely accessible resources, thereby facilitating the circulation of data value and advancing collaborative medical research.",[86,87],"Chronic Diseases","Sub-optimal Health",[89,90,91,92,93],"Real-world data","Intelligent data governance","confidential computation","trusted data matrix","chronic diseases","2026-06-03",{"date":96,"type":43},"2026-06-09",{"date":98,"type":23},"2026-05-30",{"date":47,"type":23},{"name":49,"class":50},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":18,"minAge":107,"maxAge":20,"enrollmentInfo":108,"targetDuration":4,"studyType":24,"phases":110,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":73},"100640314","standardized-study-protocol-of-percutaneous-vertebroplasty-based-on-pedicle-nine-grid-zoning-method-100640314","NCT07616583","Standardized Study Protocol of Percutaneous Vertebroplasty Based on Pedicle Nine-Grid Zoning Method","Inclusion Criteria:\n\n* Diagnosed with single-segment acute osteoporotic lumbar vertebral compression fracture (L1-L5), confirmed by typical MRI manifestations: low signal on T1-weighted imaging and high signal on T2-weighted and STIR sequences.\n* First-time reception of percutaneous vertebroplasty (PVP) surgery.\n* Complete preoperative imaging data including X-ray, CT, and MRI\u002Fbone scan.\n* Aged patients who voluntarily participate in the study and sign written informed consent.\n\nExclusion Criteria:\n\n* Patients with old vertebral compression fractures or congenital pedicle dysplasia and lesions.\n* With a history of bone tumors or other systematic bone metabolic diseases.\n* CT examination shows incomplete or ruptured posterior wall of the fractured vertebral body.\n* Failure to obtain signed informed consent.","50 Years",{"count":109,"type":23},68,[60],"The goal of this clinical trial is to verify the safety and efficacy of the pedicle \"Nine-grid Zoning Method\" in assisting percutaneous vertebroplasty (PVP) for the treatment of lumbar osteoporotic vertebral compression fractures (OVCF) in adults. It also aims to standardize the puncture path of PVP and optimize the intraoperative operation process. The main questions it aims to answer are:\n\n* Does the \"Nine-grid Zoning Method\" significantly increase the rate of achieving ideal intraoperative puncture endpoints and reduce operative time compared with the traditional pedicle puncture method?\n* Does the novel puncture method reduce intraoperative fluoroscopy times, radiation exposure, and the incidence of postoperative bone cement leakage without increasing surgical risks? Researchers will compare the modified PVP assisted by the \"Nine-grid Zoning Method\" (experimental group) with conventional PVP adopting the traditional \"10 o'clock\u002F2 o'clock\" pedicle puncture point (control group) to confirm the clinical superiority and safety of the new standardized puncture path.\n\nParticipants will:\n\n* Receive unilateral transpedicular PVP surgery via either the nine-grid zoning puncture path or the traditional puncture path for single-segment acute lumbar OVCF\n* Complete preoperative baseline examinations including bone density detection, VAS pain score, ODI functional score and SF-36 quality of life score assessment\n* Receive standardized intraoperative data recording covering operative time, fluoroscopy frequency, radiation dose, bone cement filling and leakage conditions\n* Undergo postoperative follow-up at 1 day after surgery, discharge, 3 months, 6 months and 1 year after operation, with regular imaging re-examination and scale evaluation to monitor fracture recovery and postoperative complications",[113,114],"Osteoporotic Vertebral Compression Fractures","Vertebroplasty",[116,117,118,119],"Nine-grid Area Division Method","PVP","OVCF","Vertebral pedicle puncture","2026-05-27",{"date":122,"type":43},"2026-06-01",{"date":124,"type":43},"2024-01-01",{"date":126,"type":23},"2026-12-31",{"name":49,"class":50},{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":135,"targetDuration":137,"studyType":83,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":73},"100640747","prediction-model-of-colorectal-adenoma-recurrence-carcinogenesis-risk-with-tcm-wm-multimodal-feature-fusion-100640747","NCT07611266","Prediction Model of Colorectal Adenoma Recurrence-Carcinogenesis Risk With TCM-WM Multimodal Feature Fusion","Study on the Prediction Model of Recurrence and Carcinogenesis Risk of Colorectal Adenoma Based on the Fusion of Traditional Chinese and Western Medicine Multimodal Features","Inclusion Criteria:\n\n* Meet the diagnostic criteria for colorectal adenoma (Western medicine) and the relevant TCM syndromes.\n* Aged 18 years or older.\n* Willing to undergo regular follow-up examinations (including colonoscopy and laboratory tests) and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* History of Crohn's disease, ulcerative colitis, or other malignancies.\n* Previous history of radiotherapy, chemotherapy, or gastrointestinal surgery.\n* Hereditary polyposis syndromes (e.g., familial adenomatous polyposis, MUTYH-associated polyposis, or hamartomatous polyposis syndrome).\n* Severe cognitive impairment, dementia, or mental illness.\n* Severe cardiovascular or cerebrovascular diseases, or hematological system disorders.",{"count":136,"type":23},3000,"18 Months","This project focuses on developing a risk prediction model for the recurrence and malignant transformation of colorectal adenomas by integrating multimodal features from both Traditional Chinese Medicine (TCM) and Western medicine. Led by Dr. Wei Hongtao from Beijing Friendship Hospital, Capital Medical University, the primary objective is to mine clinical characteristics from both medical systems to construct a robust predictive model. The research encompasses several key aspects: a multicenter, large-sample cohort study design with a clearly defined sample size and calculation basis; patient recruitment from multiple institutions nationwide to form training and validation sets; and strict adherence to standardized TCM and Western diagnostic criteria. Through comprehensive observation of demographic, TCM clinical (e.g., syndromes, tongue and pulse diagnosis), and Western clinical features, the study ensures data accuracy via rigorous monitoring and follow-up. Various algorithms are employed to extract and analyze these multi-source features-including endoscopic data-to build and evaluate the prediction model. Furthermore, the study aims to identify dominant subgroups to optimize TCM intervention strategies. Key performance indicators include establishing the risk model, identifying target populations, publishing high-quality papers, and training graduate students. By innovatively constructing this multimodal fusion model, the project provides a novel perspective and evidence-based foundation for the prevention and treatment of colorectal adenomas using TCM.",[140],"Colorectal Cancer Control and Prevention","2026-05-20",{"date":143,"type":43},"2026-05-28",{"date":145,"type":43},"2025-06-01",{"date":147,"type":23},"2028-11-30",{"name":49,"class":50},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":157,"targetDuration":4,"studyType":24,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":73},"100576688","fluorescence-guided-laparoscopic-endoscopic-cooperative-sentinel-lymph-node-navigation-surgery-strategy-for-early-gastric-cancerideal-stage-2b-100576688","NCT06788548","Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer（IDEAL Stage 2b）","Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer: A Multicenter Randomized Controlled Trial Study","FLECSS","Inclusion Criteria:\n\n* 1\\) Patients aged 18-80 years, regardless of gender. 2) Patients with Eastern Cooperative Oncology Group (ECOG) score ≤ 2 and American Society of Anesthesiologists (ASA) score ≤ 2 who are candidates for a curative D2 gastrectomy.\n\n  3\\) Patients without prior gastrointestinal surgery, chemotherapy, or radiotherapy.\n\n  4\\) Patients with normal liver, kidney, heart, lung, and bone marrow function (GPT × 109 \u002FL, PLT\\>109 \u002FL).\n\n  5\\) Patients capable of understanding and adhering to the research protocol. 6) Patients who can provide written informed consent, either personally or through legal representative.\n\n  7\\) Patients with cT1N0M0 gastric cancer or after non-curative ESD resection, according to the UICC TNM staging system, 8th edition.\n\nExclusion Criteria:\n\n* 1\\) Patients with a contraindication for gastroscopy. 2) Patients with uncontrollable diseases, such as coagulation disorders, epilepsy, central nervous system diseases or mental disorders, cardiopulmonary insufficiency, unstable angina, myocardial infarction, a cerebrovascular accident that occurred within 6 months, and other surgical contraindications.\n\n  3\\) Patients unable to undergo general anesthesia or surgical treatment due to conditions related to other organs, or unwilling to undergo surgery.\n\n  4\\) Patients with gastric stump cancer, recurrent gastric cancer, multiple primary malignant tumors in the abdominopelvic cavity, or a history of other malignant tumors within the previous 5 years.\n\n  5\\) Pregnant or lactating women. 6) Participants enrolled in other clinical trials. 7) Patients with undeterminable tracer staining range or contraindications to tracer use.\n\n  8\\) Patients who fail to receive or fail ESD therapy. 9) Patients who meet the absolute indication of ESD.",{"count":158,"type":23},312,[60],"The main treatment for early gastric cancer (EGC) include endoscopic submucosal dissection (ESD) and radical gastrectomy. However, appropriate treatment for patients who exceed the absolute indications and noncurative resection of ESD remains unestablished. Sentinel node navigation surgery (SNNS) enables limited lymph node resection, thereby facilitating function-preserving gastrectomy (FPG) and improving quality of life (QoL). SNNS seems to be the promising solution according to previous study, however evidence-based medicine was lacking. It is imperative to establish its safety and efficacy in patients with EGC. However, the optimal implementation of FPG remain unclear. Moreover, objective assessment of postoperative functional outcomes,remains limited.",[162],"Early Gastric Cancer",[162,164,165,166,167,168,169,170],"Sentinel Lymph Node","Basin Dissection","Laparoscopic surgery","Safety AND Efficacy","Fluorescence Guided","Laparoscopic-Endoscopic Cooperative Surgery","multicenter","2026-05-06",{"date":173,"type":43},"2026-05-11",{"date":175,"type":43},"2024-02-03",{"date":177,"type":23},"2029-12-30",{"name":49,"class":50},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":187,"targetDuration":189,"studyType":83,"phases":4,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":73},"100636505","rectal-cancer-neoadjuvant-therapy-real-world-study-100636505","NCT07566559","Rectal Cancer Neoadjuvant Therapy-Real World Study","Establishing a Strategy for Selecting Watchful Waiting and Determining the Optimal Timing for Surgery Following Neoadjuvant Therapy","RC-NAT-RWS","Inclusion Criteria:\n\n* The patient is informed and has provided written informed consent;\n* Rectal adenocarcinoma confirmed by colonoscopic biopsy and pathology, meeting the following criteria:\n\n  1. Clinical stage II\u002FIII locally advanced rectal cancer (LARC): cT1-4aN0-2M0;\n  2. The distal edge of the tumor is ≤ 10 cm from the anal verge (measured by MRI);\n  3. No distant metastasis;\n  4. Scheduled to receive neoadjuvant therapy;\n* Age ≥ 18 years, male or female。\n\nExclusion Criteria:\n\n* Presence of distant organ metastasis;\n* Multiple primary colorectal cancers;\n* History of prior malignancy (except completely cured carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin).",{"count":188,"type":23},869,"5 Years","This study aims to utilise a real-world data platform to integrate multi-omics data-including radiomics, gut microbiota, pathological quality control and liquid biopsy-to construct a multidimensional predictive model for the efficacy of rectal cancer treatment following neoadjuvant therapy. By integrating multimodal data, the study aims to accurately assess the efficacy of neoadjuvant therapy and identify patients suitable for a 'watch-and-wait' strategy, thereby achieving tumour control and preserving organ function without the need for surgery. Furthermore, it seeks to provide scientific evidence for the efficacy of the 'watch-and-wait' strategy and the selection of optimal timing for surgery, whilst validating the model's effectiveness and assessing its clinical feasibility through prospective clinical trials.",[192],"Rectal Cancer",[194,195,196],"Rectal cancer","Real world study","Neoadjuvant Therapy","2026-04-27",{"date":199,"type":43},"2026-05-05",{"date":201,"type":43},"2025-01-01",{"date":203,"type":23},"2028-12-31",{"name":49,"class":50},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":24,"phases":215,"briefSummary":216,"conditions":217,"keywords":221,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":73},"100620135","phase-2-adebrelimab-plus-apatinib-combined-with-sox-regimen-as-conversion-therapy-for-gastric-cancer-100620135","NCT07353684","Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer","Phase II Clinical Study of Adebrelimab Plus Apatinib and SOX Regimen for Conversion Therapy of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Age 18-75 years at the time of enrollment, with an estimated life expectancy of ≥ 3 months.\n* Histologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer, predominantly adenocarcinoma.\n* Unresectable locally advanced gastric or gastroesophageal junction adenocarcinoma (Stage III or IV), as determined by the investigator based on CT, MRI, and\u002For PET-CT.\n* Disease with conversion (translational) therapeutic potential, as assessed by the investigator.\n* No prior anti-tumor treatment, including chemotherapy, radiotherapy, targeted therapy, immunotherapy, or other systemic anticancer therapies.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Adequate hematologic function within 14 days prior to enrollment:\n\n  * White blood cell count ≥ 3.5 × 10⁹\u002FL.\n  * Absolute neutrophil count ≥ 1.5 × 10⁹\u002FL.\n  * Hemoglobin ≥ 90 g\u002FL (9.0 g\u002FdL).\n  * Platelet count ≥ 100 × 10⁹\u002FL.\n  * Adequate hepatic function within 14 days prior to enrollment:Total bilirubin ≤ 1.5 × upper limit of normal (ULN);ALT and AST ≤ 2.5 × ULN in patients without liver metastases;ALT and AST ≤ 5 × ULN in patients with liver metastases;Adequate renal function:Serum creatinine ≤ 1.5 × ULN;Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use effective contraception during the study and for at least 12 weeks after the last dose.\n* Male participants must be surgically sterile or agree to use effective contraception during the study and for at least 12 weeks after the last dose\n* Ability to understand and willingness to sign a written informed consent form\n* Expected to comply with study procedures and follow-up requirements\n\nExclusion Criteria:\n\n* HER2-positive gastric or gastroesophageal junction adenocarcinoma.\n* Conditions that may significantly affect oral drug absorption, including inability to swallow, persistent nausea or vomiting, chronic diarrhea, or intestinal obstruction.\n* Known hypersensitivity or allergy to adebrelimab, apatinib, oxaliplatin, S-1 (tegafur\u002Fgimeracil\u002Foteracil), or any of their excipients.\n* History of severe allergic reactions to monoclonal antibodies.\n* Active autoimmune disease or autoimmune disorders requiring systemic treatment.\n* Congenital or acquired immunodeficiency.\n* Use of systemic immunosuppressive therapy within 14 days prior to the first dose of study treatment.\n* Administration of live attenuated vaccines within 4 weeks prior to the first dose or planned during the study period.\n* Severe infection within 4 weeks prior to initiation of study treatment.\n* History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Evidence of interstitial lung disease, including pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, or severely impaired pulmonary function.\n* Uncontrolled hypertension despite at least 3 months of antihypertensive treatment.\n* Uncontrolled clinically significant cardiovascular disease.\n* High risk of severe bleeding, as judged by the investigator.\n* Peripheral neuropathy of Grade \\> 2 according to CTCAE.\n* Participation in another interventional clinical trial within 4 weeks prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for study participation.","75 Years",{"count":214,"type":23},49,[26],"This is a prospective, single-center, single-arm, open phase II clinical study. Forty-nine participants with pathologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer are scheduled to be enrolled in this study. All participants will be treated with 2 to 8 cycles of adebrelimab, apatinib, oxaliplatin, and tigio before surgery. Participants will evaluate the treatment effect after every 2 cycles of medication. By the investigator assessment as an operable subject, apatinib was discontinued for one cycle. The adjuvant treatment will be determined by the investigators based on the participants' postoperative pathology results. Participants requiring adjuvant therapy, with a postoperative interval of at least 4 weeks, but not more than 10 weeks. When the resection standard isn't met for 8 cycles of treatment, the treatment is switched to a maintenance phase, which the subject treatment regimen is determined by the investigator. During the treatment period, participants will receive the study drugs on Day 1 of each 21-day cycle until evidence of disease progression or unacceptable toxicity.",[218,219,220],"Adebrelimab","Adenocarcinoma of GE Junction","Adenocarcinoma of Stomach",[222,223,224,225],"adebrelimab","Adenocarcinoma of GE junction","Adenocarcinoma of stomach","conversion therapy","2026-04-21",{"date":228,"type":43},"2026-04-22",{"date":230,"type":43},"2025-05-11",{"date":232,"type":23},"2028-05-31",{"name":49,"class":50},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":241,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":73},"100623162","application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer-100623162","NCT07393048","Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer","ctDNA-MRD-RC","Inclusion Criteria:\n\n* 1: Signed a written informed consent form and voluntarily participated in this study\n* 2: Aged 18-75 years, regardless of sex\n* 3: Histopathologically confirmed rectal adenocarcinoma\n* 4: Clinical stage II-III as assessed by MRI (according to the AJCC 8th edition)\n* 5: Distance from the lower tumor margin to the anal verge ≤10 cm\n* 6: Surgically resectable\n* 7: Able to swallow tablets normally\n* 8: ECOG PS 0-1\n* 9: No prior antitumor therapy for rectal cancer, including radiotherapy, chemotherapy, or surgery\n* 10: Scheduled to undergo surgical treatment after completion of neoadjuvant therapy\n* 11: No surgical contraindications\n* 12: Normal function of major organs, including: complete blood count, blood biochemistry, and coagulation function\n\nExclusion Criteria:\n\n* 1: History of allergy to monoclonal antibodies, any component of tislelizumab, or capecitabine\n* 2: Prior or ongoing receipt of any tumor-directed surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc\n* 3: Presence of any active autoimmune disease or history of autoimmune disease\n* 4: History of immunodeficiency, including a positive HIV test result, other acquired or congenital immunodeficiency disorders, or history of organ transplantation or allogeneic bone marrow transplantation\n* 5: Poorly controlled cardiac clinical symptoms or diseases, including but not limited to: heart failure of NYHA class II or above, unstable angina, myocardial infarction within the past year, or clinically significant supraventricular or ventricular arrhythmia that remains poorly controlled without or despite clinical intervention\n* 6: Diagnosis of another malignancy within 5 years prior to the first use of the study drug, except for malignancies with low risk of metastasis or death (5-year survival rate \\>90%), such as adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix, which may be considered for inclusion\n* 7: Pregnant or lactating women\n* 8: Other factors, as judged by the investigator, that may lead to premature termination of the study, such as other severe diseases (including psychiatric disorders) requiring concomitant treatment, alcohol abuse, drug abuse, family or social factors, or any condition that may affect the safety or compliance of the participant",{"count":5,"type":23},"This study is a single-center, prospective, observational clinical trial enrolling patients with locally advanced rectal cancer (cT3-4aN0M0 and cT1-4aN1-2M0). By collecting tissue and blood samples at multiple timepoints, and integrating multi-omics data including ctDNA mutations, copy number variations, and mtDNA profiles, a multi-omics model will be constructed to predict the efficacy of neoadjuvant therapy for rectal cancer.",[244],"Locally Advanced Rectal Cancer (LARC)",[246,192,196,247,248],"ctDNA-MRD","Predicting the Efficacy","Detection Technology","2026-04-20",{"date":226,"type":43},{"date":252,"type":43},"2026-02-15",{"date":203,"type":23},{"name":49,"class":50},{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":24,"phases":264,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":275,"locationsCount":73},"100616995","phase-1-safety-and-tolerability-study-of-a-novel-bioartificial-liver-in-liver-failure-and-small-for-size-syndrome-100616995","NCT07312864","Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome","A Clinical Trial Assessing the Safety, Tolerability, and Exploratory Efficacy of a Novel Bioartificial Liver Therapy in Patients With Liver Failure or Small-for-Size Syndrome","Inclusion Criteria:\n\n* Patients diagnosed with liver failure (including acute, subacute\u002Facute-on-chronic, and chronic liver failure) or small-for-size syndrome\n\nExclusion Criteria:\n\n* Presence of severe extrahepatic systemic end-stage diseases\n* Uncontrollable infection or active bleeding\n* Pregnant or breastfeeding women\n* History of allergy or known severe hypersensitivity to CiPSC-derived cell products or blood products\n* Peripheral vascular collapse leading to inability to obtain venous access or collect blood\n* Unable or unwilling to provide informed consent or unable to comply with study requirements\n* Unwilling to receive CiPSC-based therapy",{"count":263,"type":23},12,[265,26],"PHASE1","The goal of this clinical trial is to evaluate the safety and tolerability of a novel bioartificial liver (CiPS-BAL) in patients with liver failure or small-for-size syndrome. The study will also collect preliminary data on clinical outcomes and laboratory parameters during treatment. The main questions it aims to answer are:\n\nIs the novel bioartificial liver system safe and well tolerated in patients with liver failure or small-for-size syndrome?\n\nWhat effects does the treatment have on liver function and other clinical and laboratory indicators?\n\nResearchers will treat participants with the CiPS-BAL system, which uses hepatocytes derived from chemically induced pluripotent stem cells (CiPS) within a bioartificial liver device.",[268,269],"Liver Failure","Small-for-Size Syndrome","2026-04-15",{"date":249,"type":43},{"date":273,"type":43},"2025-12-01",{"date":203,"type":23},{"name":49,"class":50},{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":80,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":4},"100634589","study-on-eye-brain-cross-organ-mapping-and-systemic-disease-association-based-on-multimodal-big-data-100634589","NCT07541651","Study on Eye-Brain Cross-Organ Mapping and Systemic Disease Association Based on Multimodal Big Data","Inclusion Criteria:\n\n* Eye data: Images must meet quality standards (no significant artifacts, key structures clearly visible), with complete examination records (including examination date and device model).\n* Brain data: MR images must be free of motion artifacts, with complete sequences (at least including T1-weighted imaging and MRA), and reports must confirm no technical issues.\n* Eye-brain paired cohort: Must contain at least one type of eye image (including CFP, OCT, or OCTA) along with brain MR data, and be linkable to a unique identifier and clinical information in the database\n* Clinical data: Clinical information (such as core biochemical indicators, demographic information, and necessary questionnaire items) must have a missing rate ≤30%, with standardized and clear ICD diagnostic codes, complete laboratory test data, and medical order information (including medication or follow-up recommendations)\n* Prior to initial inclusion in the study, participants must have no history of severe organic diseases (including non-curable or end-stage malignancies, severe heart failure (NYHA Class III-IV), end-stage renal disease (CKD Stage 5), decompensated cirrhosis, or significant functional impairment due to severe cerebrovascular disease sequelae, etc.).\n\nExclusion Criteria:\n\n* Ocular examinations in which key features cannot be identified due to conditions such as cataracts or vitreous hemorrhage brain MR images deemed unacceptable in quality due to factors such as metal implants\n* Clinical information (including core biochemical indicators, demographic details, essential questionnaire items, etc.) with a missing rate exceeding 30%\n* Individuals who are pregnant or lactating, those with ocular trauma, congenital ocular malformations, or severe organic diseases.",{"count":283,"type":23},208000,"This project integrates multimodal eye data (CFP, OCT, OCTA) from 50,000 cases, brain MR data from 150,000 cases, and ICD diagnoses, medical orders, and test results from an eye-brain paired cohort of 8,000 cases to construct an eye-brain cross-modal mapping model and an eye-brain-systemic disease association model. It aims to clarify the quantitative associations between multimodal ocular features and brain structural and vascular characteristics as well as systemic disease ICD diagnoses, thereby uncovering the cross-organ and cross-modal linkage mechanisms between the eye and brain. Ultimately, it seeks to achieve mapping and prediction of brain imaging features based on ocular data, enable ocular-based diagnosis and prediction of various diseases, and contribute significantly to early disease screening, risk stratification, and optimization of clinical diagnosis and treatment.",[286,287,288,289,290],"Cataract","Vitreous Hemorrhage","Diabetic Eye Diseases","Cerebral Small Vessel Disease","Cerebrovascular Stenosis","2026-04-14",{"date":226,"type":43},{"date":294,"type":23},"2026-04-25",{"date":296,"type":23},"2029-12-31",{"name":49,"class":50},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":305,"targetDuration":4,"studyType":24,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":73},"100627840","phase-1-novel-calcium-channel-modulators-in-rls-and-variants-efficacy--safety-100627840","NCT07453862","Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety","Observation of Efficacy and Safety of Novel Calcium Channel Modulators in the Treatment of Restless Legs Syndrome and Its Variant Subtypes","Inclusion Criteria:\n\n* 1\\. Aged 18-75 years, regardless of gender.\n* 2\\. Meets the diagnostic criteria for typical Restless Legs Syndrome (RLS) (IRLSSG criteria) or variant RLS confirmed by a neurologist.\n* 3\\. Moderate to severe RLS (IRLS score ≥11).\n* 4\\. Able to understand and comply with the study protocol, and provides written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Secondary RLS (e.g., iron deficiency anemia with serum ferritin \\\u003C30μg\u002FL, renal dysfunction with eGFR \\\u003C30ml\u002Fmin, pregnancy\u002Flactation, drug-induced RLS with unadjustable medications).\n* 2\\. Severe central nervous system diseases (e.g., status epilepticus, severe dementia, stroke within 3 months).\n* 3\\. Severe cardiovascular diseases (e.g., congestive heart failure, uncontrolled hypertension with SBP≥180mmHg or DBP≥110mmHg).\n* 4\\. Severe liver or kidney dysfunction (ALT\u002FAST \\>3×ULN, eGFR \\\u003C30mL\u002Fmin\u002F1.73m²).\n* 5\\. Active mental illnesses (e.g., schizophrenia, acute bipolar disorder).\n* 6\\. Hypersensitivity to Keligabalin Benzenesulfonic Acid or its excipients.\n* 7\\. Participation in other clinical trials within 1 month, inability to cooperate with follow-up, or history of substance abuse.\n* 8\\. Pregnancy or lactation.",{"count":306,"type":23},20,[265],"The goal of this \\[study type: clinical trial\\] is to \\[primary purpose: evaluate the efficacy and safety of a novel calcium channel modulator in treating Restless Legs Syndrome (RLS) and its variant subtypes\\] in \\[describe participant population\u002Fprimary condition: adult patients aged 18-75 years with confirmed RLS or its variant subtypes, who meet the study's eligibility criteria\\]. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\n* Does the novel calcium channel modulator improve RLS-related symptoms (assessed by the International Restless Legs Syndrome Study Group Rating Scale, IRLS) after the treatment period?\n* What is the safety profile (incidence of adverse events) of this calcium channel modulator in RLS patients?\n\nParticipants will \\[describe the main tasks participants will be asked to do, interventions they'll be given\\]:\n\n* Receive oral administration of the novel calcium channel modulator (40mg twice daily) for 12 consecutive weeks\n* Complete scheduled follow-up visits for symptom assessments, safety monitoring, and questionnaire completion",[310,311],"Restless Leg Syndrome (RLS)","Variant Restless Legs Syndrome","2026-03-03",{"date":314,"type":43},"2026-03-06",{"date":316,"type":23},"2026-03-10",{"date":318,"type":23},"2027-08-31",{"name":49,"class":50},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":328,"conditions":329,"keywords":333,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":4},"100627593","hepatic-and-splenic-microcirculatory-perfusion-for-ruling-out-high-risk-varices-in-patients-with-hepatitis-b-related-cirrhosis-100627593","NCT07450651","Hepatic and Splenic Microcirculatory Perfusion for Ruling Out High-Risk Varices in Patients With Hepatitis B-Related Cirrhosis","Development of a Hepato-Splenic Microcirculatory Perfusion Model Using IVIM MRI to Rule Out High-Risk Varices in Patients With Compensated Hepatitis B-Related Cirrhosis","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Clinically diagnosed with chronic hepatitis B cirrhosis\n3. Acceptance of upper gastrointestinal endoscopy screening or evaluation.\n4. Abdominal MRI examination with IVIM sequence within 6 months prior to endoscopy.\n\nExclusion Criteria:\n\n1. Co-existing chronic liver diseases.\n2. Previous portosystemic shunt treatment or splenectomy.\n3. A history of treatment for upper gastrointestinal varices that affects the assessment.\n4. Severe hepatic or splenic iron deposition.\n5. Decompensated cirrhosis.\n6. Co-existing malignancies.",{"count":58,"type":23},"Background:\n\nChronic hepatitis B (CHB)-related cirrhosis is a common cause of portal hypertension, which leads to the development of gastroesophageal varices (EGVs). High-risk varices (HRV) are associated with a higher risk of bleeding and require timely interventions. Endoscopy is the gold standard for diagnosing HRV but is invasive and not suitable for routine screening in large populations.\n\nObjective:\n\nThis study aims to develop a noninvasive model based on hepatic and splenic microcirculatory perfusion parameters derived from intravoxel incoherent motion (IVIM) magnetic resonance imaging (MRI) to predict and rule out HRV in patients with compensated CHB-related cirrhosis receiving antiviral therapy.\n\nMethods:\n\nThis observational, retrospective study will include patients with compensated CHB-related cirrhosis who have undergone both esophagogastroduodenoscopy (EGD) and IVIM MRI. Microcirculatory perfusion parameters will be extracted from IVIM images using a biexponential model, and their ability to predict HRV will be assessed.\n\nOutcomes:\n\nThe study will validate the performance of the Hepato-Splenic Microcirculatory Perfusion Model (HSMP) in ruling out HRV compared to conventional noninvasive tests like APRI, FIB-4, and LSM. The model's diagnostic accuracy will be evaluated with a focus on reducing unnecessary endoscopic procedures.\n\nSignificance:\n\nIf successful, this model could reduce the need for invasive endoscopy and improve the management of cirrhosis patients by providing a safer and more accessible screening tool for HRV.",[330,331,332],"Hepatitis B Virus Related Cirrhosis","Portal Hypertension Related to Cirrhosis","Esophagogastric Varices",[334,335,336,337,338,339,340],"Intravoxel incoherent motion","Hepatic microcirculation","Splenic microcirculation","High-risk varices","Baveno VI criteria","FIB-4","Liver stiffness measurement","2026-03-01",{"date":343,"type":43},"2026-03-05",{"date":345,"type":23},"2026-02",{"date":347,"type":23},"2026-10",{"name":49,"class":50},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":24,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":73},"100626916","digital-rehabilitation-for-gastric-cancer-surgery-after-neoadjuvant-therapy-100626916","NCT07441850","Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy","The Effect of Perioperative Rehabilitation Programme Delivered Via a Smart Phone Based Digital Platform in Patients Undergoing Neoadjuvant Therapy for Gastric Cancer Surgery: Study Protocol for a Randomised Controlled Trial","Inclusion Criteria:\n\n* patients aged between 18 and 70 years;\n* patients with histologically confirmed resectable adenocarcinoma of the oesophago gastric junction or stomach;\n* patients referred by a multidisciplinary team (MDT) for neoadjuvant therapy;\n* patients able to use a smartphone and the digital follow up platform, and willing to comply with regular follow up assessments;\n* patients who provide written informed consent.\n\nExclusion Criteria:\n\n* presence of distant metastasis;\n* severe cardiopulmonary disease or other contraindications precluding completion of the 6MWT or participation in exercise training;\n* concurrent other malignant tumours;\n* suspected recurrent gastric cancer;\n* cognitive impairment, communication barriers, or psychiatric conditions that would prevent compliance with the study procedures;\n* women who are pregnant, lactating, or planning a pregnancy.","70 Years",{"count":358,"type":23},186,[60],"The goal of this clinical trial is to investigate the effects of a perioperative multimodal rehabilitation program on the incidence of postoperative complications and perioperative clinical indexes including functional capacity, nutritional and psychological status in patients with gastric cancer undergoing neoadjuvant therapy. Besides the investigators also develop a smart phone based digital platform aiming to evaluate its effectiveness in improving patient adherence, compared with the conventional telephone supervision approach. The main questions it aims to answer are:\n\n* Can the perioperative multimodal rehabilitation program reduce postoperative complications in patients with gastric cancer undergoing neoadjuvant therapy?\n* Can the smart phone based digital platform improve patients' adherence compared to traditional telephone supervision?\n* Can the perioperative multimodal rehabilitation program improve the perioperative clinical indicators of patients with gastric cancer undergoing neoadjuvant therapy, including functional capacity, nutritional status and psychological condition? The investigators will compare the perioperative multimodal rehabilitation program with the standard treatment alone to determine whether this program has the effects mentioned above.\n\nParticipants will follow the perioperative multimodal rehabilitation program from neoadjuvant therapy through to four weeks after discharge.",[362],"Gastric Cancer",[364,365,366,367,368,369],"Gastric cancer","Neoadjuvant therapy","Digital health","Randomized control trial","Perioperative rehabilitation","Multimodal intervention","2026-02-24",{"date":372,"type":43},"2026-03-02",{"date":374,"type":43},"2026-02-01",{"date":376,"type":23},"2027-03-01",{"name":49,"class":50},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":18,"minAge":386,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":24,"phases":390,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":402,"leadSponsor":403,"locationsCount":73},"100530845","adverse-cardiovascular-events-during-painless-gastroscopy-diagnosis-and-treatment-in-elderly-frail-patients-100530845","NCT06192082","Adverse Cardiovascular Events During Painless Gastroscopy Diagnosis and Treatment in Elderly Frail Patients","Clinical Study About Impacts of Anesthesia Methods on Adverse Cardiovascular Events During Painless Gastroscopy Diagnosis and Treatment in Elderly Frail Patients","frail","Inclusion Criteria:\n\n1. Age greater than 65 years old, regardless of gender\n2. ASA is classified as Class II and III;\n3. BMI 18-28 kg\u002Fm2;\n4. Patients undergoing examination or treatment outside the operating room;\n5. FRAIL scale score ≥ 3 points 6 The patient voluntarily participated in this study and signed an informed consent form.\n\nExclusion Criteria:\n\n1 Those who are allergic or contraindicated to drugs such as benzodiazepines, opioids, propofol, and their drug components;\n\n2\\. Acute heart failure; Unstable angina pectoris; Myocardial infarction occurred within 6 months prior to screening; Resting electrocardiogram heart rate\\\u003C50 beats\u002Fminute; Third degree atrioventricular transmission delay; Severe arrhythmia; Moderate to severe heart valve disease;\n\n3\\. Patients with severe respiratory diseases (acute respiratory infections, acute exacerbations of chronic obstructive pulmonary disease, uncontrolled asthma, etc.);\n\n4\\. Patients who have not received formal antihypertensive treatment or have poor blood pressure control;\n\n5\\. Patients with traumatic brain injury, possible presence of intracranial hypertension, cerebral aneurysms, history of cerebrovascular accidents, and central nervous system diseases;\n\n6\\. Individuals with mental system diseases (schizophrenia, mania, bipolar disorder, mental disorder, etc.), long-term history of taking psychotropic drugs, and cognitive impairment;\n\n7\\. Other situations that have been determined by the researcher to be unsuitable for inclusion.","65 Years","100 Years",{"count":389,"type":23},226,[60],"This study aims to compare the effects of conscious sedation and intravenous general anesthesia on cardiovascular events in frail patients undergoing digestive endoscopy diagnosis and treatment.",[393],"Anesthesia",[395,396,397],"gastroscopy","frail patients","adverse cardiovascular events","2026-02-11",{"date":400,"type":43},"2026-02-12",{"date":124,"type":43},{"date":400,"type":23},{"name":49,"class":50},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":411,"targetDuration":4,"studyType":24,"phases":413,"briefSummary":414,"conditions":415,"keywords":419,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":428,"leadSponsor":430,"locationsCount":73},"100623500","phase-2-short-course-radiotherapy-combined-with-chemotherapy-and-immunotherapy-in-mid-low-locally-advanced-rectal-cancer-100623500","NCT07397442","Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","A Prospective, Phase II, Single-Arm Study on the Efficacy and Safety of Neoadjuvant Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. ECOG performance status score 0-2.\n3. Rectal adenocarcinoma confirmed by colonoscopic pathology, with pMMR or MSS.\n4. Imaging studies confirm no distant metastasis or lateral lymph node metastasis; MRI staging is II\u002FIII (excluding T4b, N1c, N2) and any positive lymph nodes (if present) are confined within the mesorectum.\n5. MRI shows the distal margin of the tumor is ≤10 cm from the anal verge, and the mesorectal fascia (MRF) is negative.\n6. The longest diameter of the rectal cancer lesion is ≥10 mm on baseline CT or MRI (meeting the definition of a \"measurable lesion\" per RECIST 1.1 criteria).\n7. Willing and able to comply with the study procedures.\n8. Consent to the use of tissue and blood samples by the investigator for medical research purposes.\n9. No prior history of radiotherapy or immunotherapy.\n10. No history of immune system diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, pemphigus, dermatomyositis, mixed connective tissue disease, autoimmune hemolytic anemia, ulcerative colitis, HIV infection, etc.).\n11. No history of endocrine system diseases (e.g., hyperthyroidism, hypothyroidism, thyroid nodules, thyroiditis, type 1 diabetes, type 2 diabetes, gestational diabetes, other specific types of diabetes, Cushing's syndrome, primary aldosteronism, pheochromocytoma, adrenal insufficiency, pituitary adenoma, anterior pituitary hypofunction, acromegaly, gigantism, polycystic ovary syndrome, precocious puberty, hypogonadism, hyperparathyroidism, hypoparathyroidism, etc.).\n12. No severe cardiac, pulmonary, hepatic, or renal dysfunction.\n13. No jaundice or gastrointestinal obstruction.\n14. No concurrent acute infection.\n15. Subjects must undergo all required baseline laboratory assessments, and results must be obtained within 1 week before enrollment. Laboratory values must meet the following criteria (per CTCAE 5.0):\n\n    1. White blood cell count ≥2000\u002FμL.\n    2. Neutrophil count ≥1500\u002FμL.\n    3. Platelet count ≥100×10³\u002FμL.\n    4. Hemoglobin ≥9.0 g\u002FdL.\n    5. Creatinine: serum creatinine ≤1.5 × upper limit of normal (ULN) or creatinine clearance \\>50 mL\u002Fmin (calculated using the Cockcroft-Gault formula).\n    6. Creatinine clearance for females = \\[140 - age (years)\\] × weight (kg) × 0.85 ÷ \\[72 × serum creatinine (mg\u002FdL)\\].\n    7. Creatinine clearance for males = \\[140 - age (years)\\] × weight (kg) × 1.00 ÷ \\[72 × serum creatinine (mg\u002FdL)\\].\n    8. Aspartate aminotransferase (AST) ≤3 × ULN, alanine aminotransferase (ALT) ≤3 × ULN, total bilirubin ≤1.5 × ULN.\n16. No psychiatric\u002Fpsychological disorders affecting social functioning.\n17. Women of childbearing potential must have a negative serum pregnancy test (blood HCG) within 1 week before enrollment.\n18. Women of childbearing potential and men who are sexually active with women of childbearing potential must agree to use appropriate contraceptive methods.\n\nExclusion Criteria:\n\n1. Multifocal cancer, or concomitant other malignant tumors.\n2. Received any anti-tumor therapy for other malignant tumors within the past 5 years.\n3. Underwent major surgery recently (within 6 months).\n4. Presence of multiple factors affecting oral drug absorption (e.g., inability to swallow, nausea, vomiting, chronic diarrhea, intestinal obstruction, etc.).\n5. Any uncontrolled, severe comorbid diseases.\n6. Allergy to any component of the study medication.\n7. Life expectancy less than 5 years for any reason.\n8. Planning to undergo or previously underwent organ\u002Fbone marrow transplantation.\n9. Received immunosuppressive agents or glucocorticoid therapy aimed at suppressing immune responses within 1 month before enrollment.\n10. For patients with a history of central nervous system diseases, the investigator will determine whether their current condition allows them to provide informed consent or comply with the study procedures, and subsequently decide whether they can be enrolled.\n11. Other diseases or conditions that may prevent completion of the study treatment (e.g., alcoholism, drug addiction, etc.).\n12. Pregnant or lactating women.",{"count":412,"type":23},19,[26],"The goal of this clinical trial is to test a new combination treatment for locally advanced rectal cancer (cancer in the lower or middle part of the rectum that has not spread to distant organs). The study aims to increase the chance of making the tumor disappear completely (called \"complete response\") and improve the quality of life by increasing the rate of anal sphincter preservation (avoiding permanent colostomy bags).\n\nThe main questions it aims to answer are:\n\nDoes the combination of short-course radiation therapy, two types of immunotherapy drugs (Qibeian and Aike), and chemotherapy (XELOX) increase the complete response rate to over 50%? Is this combination treatment safe, and what are the side effects? Can this treatment help more patients keep their anal function and avoid permanent stomas?\n\nThis is a single-arm study, meaning all participants will receive the experimental treatment (there is no placebo or control group).\n\nParticipants will:\n\nReceive short-course radiation therapy (25 Gy total, given once daily for 5 consecutive days). The radiation will target only the tumor and visible lymph nodes, intentionally avoiding unaffected lymph node areas to protect the immune system.\n\nReceive Qibei'an (a dual immunotherapy drug targeting both PD-1 and CTLA-4) once, 2 days after completing radiation.\n\nReceive Camrelizumab (a PD-1 immunotherapy drug) three times, combined with XELOX chemotherapy.\n\nReceive XELOX chemotherapy (Oxaliplatin ivgtt on Day 1, plus Capecitabine pills taken twice daily for 14 days, for each cycle) for up to 3 cycles.\n\nUndergo detailed assessments after treatment, including MRI scans, colonoscopy with biopsies, and blood tests (including ctDNA tests), to determine if the tumor has disappeared or if surgery is needed.\n\nAttend regular follow-up visits for up to 5 years after treatment (or surgery) to monitor for recurrence and assess quality of life.\n\nThe study will enroll approximately 19 patients at Beijing Friendship Hospital, Capital Medical University. An independent safety monitoring board will regularly review the data to ensure participant safety.",[416,417,418],"Rectal Cancer, Adenocarcinoma","Rectal Cancer Stage II","Rectal Cancer Stage III",[420,421,422,423,424],"locally advanced rectal cancer","short-course radiotherapy","anti-PD1","anti-CTLA4","complete response","2026-02-09",{"date":398,"type":43},{"date":341,"type":23},{"date":429,"type":23},"2033-02-28",{"name":49,"class":50},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":438,"targetDuration":4,"studyType":24,"phases":440,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":450,"locationsCount":73},"100624038","phase-4-rivaroxaban-in-idiopathic-membranous-nephropathy-100624038","NCT07404436","Rivaroxaban in Idiopathic Membranous Nephropathy","Efficacy of Rivaroxaban for Thromboprophylaxis in Idiopathic Membranous Nephropathy: A Prospective, Single-Center, Randomized Controlled Trial","Inclusion Criteria:\n\nAge 18-80 years, either sex. Kidney biopsy findings on both light microscopy and electron microscopy consistent with idiopathic membranous nephropathy (IMN).\n\nIMN patients at high risk of thrombosis: meeting the diagnostic criteria for nephrotic syndrome and having serum albumin \\\u003C25 g\u002FL. Normal renal function (normal creatinine clearance).\n\nExclusion Criteria:\n\nPrior thrombotic events, such as pulmonary embolism, renal vein thrombosis, or lower-extremity deep vein thrombosis.\n\nPulmonary diseases that may affect the accuracy of ventilation-perfusion (V\u002FQ) scanning for diagnosing pulmonary embolism, such as pulmonary infection\u002Finflammation, lung tumors, or chronic obstructive pulmonary disease.\n\nInability to undergo V\u002FQ scanning, e.g., right-to-left congenital cardiac shunt, prior allergy to radiopharmaceuticals, or inability to cooperate with the examination.\n\nClinically significant active bleeding. Pregnant or breastfeeding women. Acute myocardial infarction and\u002For acute stroke, or atrial fibrillation. Active infection or active malignancy. Coagulation abnormalities; hepatic dysfunction (aminotransferases ≥3× the upper limit of normal); or thrombocytopenia (platelet count \\\u003C100×10\\^9\u002FL).",{"count":439,"type":23},134,[441],"PHASE4","Through a prospective, single-center, randomized controlled trial, we aim to determine the thromboprophylactic efficacy of rivaroxaban in patients with idiopathic membranous nephropathy (IMN). IMN patients at high risk of thrombosis and low risk of bleeding will be enrolled and randomly assigned to a rivaroxaban group or a control group (receiving warfarin). Prophylactic anticoagulation will be administered with rivaroxaban or warfarin accordingly. Over the 6 months following initiation of prophylactic anticoagulation, the incidence of the primary efficacy endpoint (a composite of pulmonary embolism, deep vein thrombosis, and lower-extremity deep vein thrombosis) and the safety endpoint (bleeding events) will be compared between the two groups.",[444],"Idiopathic Membranous Nephropathy","2026-02-05",{"date":398,"type":43},{"date":448,"type":43},"2024-01-05",{"date":126,"type":23},{"name":49,"class":50},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":356,"enrollmentInfo":458,"targetDuration":460,"studyType":83,"phases":4,"briefSummary":461,"conditions":462,"keywords":464,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":471,"leadSponsor":473,"locationsCount":73},"100620511","eye-brain-kidney-in-ckd-100620511","NCT07358572","Eye-Brain-Kidney in CKD","A Study on the Eye-Brain-Kidney Interaction Mechanisms in Chronic Kidney Disease Based on Multimodal Magnetic Resonance Imaging","Inclusion Criteria:\n\n1. Aged 18-70 years.\n2. Patients clinically diagnosed with CKD stages 1-5.\n3. No contraindications for MRI examination (e.g., cardiac pacemaker, claustrophobia, cochlear implant, hearing aid, coronary stents implanted before 2015) and able to complete the MRI scan.\n\nExclusion Criteria:\n\n1. Patients with recent or prior cerebral hemorrhage or cerebral infarction.\n2. History of epileptic seizures or psychiatric disorders.\n3. Patients with claustrophobia.\n4. Pregnant or lactating patients.\n5. Presence of other central nervous system diseases (e.g., tumor, trauma).\n6. Unstable angina, congestive heart failure (NYHA class III or IV), or acute myocardial infarction.\n7. Any systemic or other diseases deemed unsuitable for clinical trial participation.",{"count":459,"type":23},1500,"3 Years","The goal of this observational study is to learn about the interaction between the eyes, brain, and kidneys in adult patients with Chronic Kidney Disease (CKD). The main question it aims to answer is:\n\nDo changes in the brain's network connectivity and the retina's blood vessels correlate with cognitive decline and kidney function in CKD patients? Participants with CKD who are already undergoing clinical care will complete cognitive tests and questionnaires, have non-invasive MRI scans of their brain and kidneys, and undergo non-invasive eye imaging (OCT\u002FOCTA) of their retinas.",[463],"Chronic Kidney Diseases",[465,466],"Multimodal magnetic resonance imaging","Montreal Cognitive Assessment","2026-01-25",{"date":469,"type":43},"2026-01-27",{"date":273,"type":43},{"date":472,"type":23},"2031-12-31",{"name":49,"class":50},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":356,"enrollmentInfo":481,"targetDuration":4,"studyType":24,"phases":483,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":73},"100621370","phase-2-golidocitinib-combined-with-selinexor-for-caebvd-100621370","NCT07369739","Golidocitinib Combined With Selinexor for CAEBVD","Golidocitinib Combined With Selinexor for the Treatment of Chronic Active Epstein-Barr Virus Disease (CAEBVD): A Multicenter, Prospective, Single-arm Clinical Study","Inclusion Criteria:\n\n1. CAEBVD diagnosed in accordance with the Consensus on the Diagnosis and Treatment of Chronic Active Epstein-Barr Virus Disease (2025 Edition).\n2. Aged ≥ 18 years and ≤ 70 years, regardless of gender.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n4. Before the initiation of the study, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); total bilirubin ≤ 2 × ULN; serum creatinine ≤ 1.5 × ULN.\n5. Routine blood test: absolute neutrophil count ≥ 1 × 10#\u002FL; platelet count ≥ 50 × 10#\u002FL; hemoglobin ≥ 60 g\u002FL.\n6. Coagulation function test requirements: international normalized ratio (INR) ≤ 2.0; prothrombin time (PT) ≤ 1.5 × ULN.\n7. Women of childbearing potential must have a negative pregnancy test result, and be willing to take effective contraceptive measures during the trial period and for ≥ 12 months after the last dose; all male subjects must take contraceptive measures during the trial period and for ≥ 6 months after the last dose.\n8. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Evidence of EBV-associated hematological diseases or malignancies, such as hemophagocytic lymphohistiocytosis, lymphomatoid granulomatosis, post-transplant lymphoproliferative disorder, non-Hodgkin's lymphoma, Burkitt lymphoma, nasopharyngeal carcinoma, and gastric cancer.\n2. Having received any of the following treatments: prior treatment with any JAK inhibitor; administration of any investigational drug within 12 weeks prior to the first dose of the study drug; concurrent enrollment in another clinical study.\n3. A history of other primary malignancies within 5 years prior to the first dose of the study drug, excluding locally curable malignancies that have received curative treatment (e.g., basal or squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast).\n4. A history of organ transplantation (e.g., liver transplantation, kidney transplantation).\n5. Planned hematopoietic stem cell transplantation during the study period.\n6. Active hepatitis B (defined as positive hepatitis B surface antigen \\[HBsAg\\] at screening, or a peripheral blood hepatitis B virus DNA titer \\> 1×10³ copies\u002FmL); active hepatitis C (defined as positive anti-hepatitis C virus antibody \\[HCV-Ab\\] and HCV-RNA at screening); positive serum HIV antigen or antibody; a history of syphilis.\n7. Having undergone major surgery within 4 weeks prior to the first dose, or anticipating the need for major surgery during the study period.\n8. Pregnant or lactating women.\n9. A history of severe mental illness or drug abuse.\n10. Uncontrolled infections (including pulmonary infection, intestinal infection); active major visceral hemorrhage (including gastrointestinal bleeding, alveolar hemorrhage, intracranial hemorrhage).\n11. Hypersensitivity to the components of the study drug, or a history of severe allergic diathesis.\n12. Patients who are unable to comply with the requirements during the trial and\u002For follow-up phase.",{"count":482,"type":23},28,[26,27],"This study is a multicenter, prospective, single-arm clinical investigation, with patients with CAEBVD as the main research subjects, to evaluate the effectiveness of the combined treatment regimen of golidocitinib and selinexor.",[486,487,488],"Lymphohistiocytosis","EBV","CAEBV","2026-01-17",{"date":469,"type":43},{"date":492,"type":43},"2026-01-01",{"date":494,"type":23},"2028-01-01",{"name":49,"class":50},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":18,"minAge":503,"maxAge":356,"enrollmentInfo":504,"targetDuration":4,"studyType":24,"phases":505,"briefSummary":506,"conditions":507,"keywords":509,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":73},"100619032","phase-2-prospective-single-arm-clinical-trial-of-go-regimen-for-hlh-100619032","NCT07339345","Prospective Single-Arm Clinical Trial of GO Regimen for HLH.","Prospective Single-Arm Clinical Trial of Golidocitinib Monotherapy for Hemophagocytic Lymphohistiocytosis.","Inclusion Criteria:\n\n1. Researchers evaluate patients with newly diagnosed or refractory\u002Frelapsed HLH disease.\n2. Definite diagnosis of HLH: molecular diagnosis consistent with pHLH, or at least 5 of the 8 criteria in the HLH-2004 diagnostic criteria.\n3. Patients who are currently unsuitable or unable to undergo allo-HSCT.\n4. Researchers estimate that the expected survival period exceeds one month.\n5. Patients must be at least 14 years of age and no older than 70 years of age, with no gender restrictions.\n6. Before the study began, TB was ≤10 times the upper limit of normal; Cr was ≤1.5 times the normal value.\n7. Serum HIV antigen or antibody negative。\n8. HCV antibody negative, or HCV antibody positive but HCV RNA negative.\n9. .HBsAg and HBcAb are both negative. If either of the above is positive, peripheral blood hepatitis B virus DNA titer testing is required, with a titer of less than 1×10³ copies\u002Fml.\n10. Echocardiography showed LVEF ≥ 50%.\n11. Women of childbearing age must be confirmed as not pregnant by a pregnancy test and must be willing to use effective contraception during the study period and for at least 12 months after the last dose; all male participants must use contraception during the study period and for at least 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Heart function above grade II(including II) (NYHA).\n2. Pregnancy or lactating Women and reproductive-age patients who refused to use appropriate contraceptive measures during this trial.\n3. Individuals who are allergic to GO or have a severe allergic constitution.\n4. Active bleeding of the internal organs.\n5. uncontrollable infection.\n6. Severe mental illness.\n7. History of non-melanoma skin cancer.\n8. Unable to comply during the trial and\u002For follow-up phase. Participate in other clinical research at the same time.","14 Years",{"count":482,"type":23},[26,27],"This study aims to investigate the efficacy and safety of Golidocitinib(GO) monotherapy in the treatment of hemophagocytic lymphohistiocytosis.",[508],"Lymphohistiocytosis, Hemophagocytic",[510,511],"Hemophagocytic Lymphohistocytosis","Golidocitinib","2026-01-12",{"date":514,"type":43},"2026-01-14",{"date":516,"type":43},"2025-06-27",{"date":518,"type":23},"2027-06-27",{"name":49,"class":50},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":527,"targetDuration":4,"studyType":24,"phases":529,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":540},"100540141","phase-2-a-series-of-neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-for-locally-advanced-rectal-cancer-100540141","NCT06312982","A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer","A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study","Inclusion Criteria:\n\n1. Signed a written informed consent form and volunteered to join the study;\n2. .Age: 18-75 years old, male or female;\n3. Pathohistologically confirmed rectal adenocarcinoma, along with immunohistochemical results of pMMR or genetic test results of MSS;\n4. The baseline clinical stage assessed by MRI was T1-2N1-2M0 or T3N0-2M0, MRF (-), lateral lymph nodes (-);\n5. The lower tumor margin is 10cm away from the anal margin;\n6. Surgical resection;\n7. Ability to swallow tablets normally;\n8. ECOG PS 0-1；\n9. Have not received any anti-tumor treatment for rectal cancer, including radiotherapy, chemotherapy, surgery, etc.;\n10. Plan to undergo surgery after the completion of the neoadjuvant therapy;\n11. No contraindications to surgery;\n12. Main organ function is normal.\n\nExclusion Criteria:\n\n1. Previous history of allergy to monoclonal antibodies, any component of tislelizumab,and capecitabine;\n2. Previously has received or is receiving any of the following treatments:\n\n   A)Any tumor-specific surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc; B)Treatment with immunosuppressive drugs or systemic hormones within 2 weeks of first use (dose\\> 10mg \u002F day prednisone or equivalent dose); inhaled or topical steroids and dose\\> 10mg \u002F day prednisone or equivalent dose of adrenocorticoid replacement in the absence of active autoimmune disease; C)Having received a live attenuated vaccine within 4 weeks before the first use of the study drug; D)Major surgery or severe trauma within 4 weeks before the first use of study drug;\n3. History of any active autoimmune or autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (considered after hormone replacement therapy); patients with psoriasis or asthma \u002F allergy in childhood and adults without any intervention, but patients requiring medical intervention with bronchodilators should not be included;\n4. A history of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency disease, or a history of organ transplantation or allogeneic bone marrow transplantation;\n5. Not well controlled cardiac clinical symptoms or disease, including but not limited to: such as (1) grade NYHA II above heart failure, (2) unstable angina, (3) myocardial infarction within 1 year, (4) clinical meaningful supraventricular or ventricular arrhythmia without clinical intervention or clinical intervention still poor control;\n6. Severe infection (Grade CTCAE\\> 2) within 4 weeks prior to the first use of study drug, Such as severe pneumonia, bacteremia, infection complications requiring hospitalization; Baseline chest imaging indicated the presence of active lung inflammation, presence of symptoms and signs and signs of infection within 14 days prior to the first administration of study drug or need for oral or intravenous antibiotics, Except for the preventive use of antibiotics; Found active tuberculosis infection by history or CT, Or those with a history of active tuberculosis infection within 1 year prior to enrollment, Or those with a history of active tuberculosis infection more than 1 year ago but without formal treatment;\n7. Presence of active hepatitis B (HBV DNA 2000 IU \u002F mL or 104copies \u002F mL), hepatitis C (positive for hepatitis C antibody, and HCV RNA above the lower limit of detection of the analytical method);\n8. A diagnosis of other malignancies within 5 years prior to the first use of study drug, unless a malignancy with low risk of metastasis or death (5-year survival\\> 90%), such as adequately treated skin basal cell carcinoma or squamous cell carcinoma in situ, are considered;\n9. Women in pregnancy or lactation;\n10. Other factors, as judged by the investigator, may lead to forced termination of the study, such as other serious illness (including mental illness), alcohol, substance abuse, family or social factors, which may affect the safety or compliance of the subject.",{"count":528,"type":23},375,[26,27],"The goal of this clinical trial is to compare the efficacy and safety of neoadjuvant chemoradiotherapy combined with tirelizumab compared with neoadjuvant chemoradiotherapy alone for neoadjuvant therapy in patients with locally advanced rectal cancer.\n\nThe main questions it aims to answer are:\n\nTo evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with tirelizumab compared with neoadjuvant chemoradiotherapy alone for neoadjuvant therapy in patients with locally advanced rectal cancer To assess rectal or anal retention as well as quality of life. Participants will receive a long course of NCRT (50 Gy \u002F 25f, capecitabine 850-1000 mg \u002F m2, BID, PO, D1-D5, QW) within the first 5 weeks. In regard to tumor immunotherapy, enrolled patients will receive tislelizumab (200 mg, iv) on the first day at week 2,5, and 8 after initiation of radiotherapy. Thereafter, patients will be treated with two 14-day cycles of the CAPOX（Q 3 w; D1 oxaliplatin, 130mg\u002Fm2,iv.gtt; D1-D14, capecitabine, 850-1000mg \u002F m2, BID, PO）regimen. Two CAOPX regimens were treated one week apart.",[532],"Locally Advanced Rectal Carcinoma",{"date":534,"type":43},"2026-01-13",{"date":536,"type":43},"2024-03-16",{"date":538,"type":23},"2026-12-01",{"name":49,"class":50},2,{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":548,"targetDuration":4,"studyType":24,"phases":550,"briefSummary":551,"conditions":552,"keywords":557,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":570,"locationsCount":73},"100617225","phase-2-iparomlimab-and-tuvonralimab-ql1706-combined-with-chemotherapy-for-previously-untreated-advanced-or-metastatic-gastric-or-gastroesophageal-junction-cancer-100617225","NCT07315854","Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","A Prospective, Single-Center, Exploratory Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy in the Treatment of Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","Inclusion Criteria:\n\n* Voluntarily participate in the clinical study; fully understand and are informed about the study and sign the Informed Consent Form (ICF); willing to follow and able to complete all trial procedures.\n* Age 18-80 years, gender is not limited.\n* Patients with locally advanced unresectable, recurrent unresectable, or metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) confirmed by imaging and other examinations, and histopathologically confirmed as adenocarcinoma.\n* Provide a report confirming HER2 overexpression or amplification negativity; defined as IHC 0\u002F1+, or IHC 2+ with FISH\u002FISH negative.\n* No prior systemic therapy for advanced or metastatic GC\u002FGEJC (including anti-HER-2 therapy). Patients who have received adjuvant or neoadjuvant therapy (including chemotherapy, radiotherapy, or chemoradiotherapy) for GC\u002FGEJC are eligible if the time to first recurrence or disease progression is greater than 6 months from the end of the last treatment. Prior use of anti-tumor Traditional Chinese Medicine preparations is allowed but must be discontinued at least 2 weeks before enrollment.\n* ECOG performance status score of 0 or 1.\n* Must have at least one measurable lesion according to RECIST v1.1 definitions.\n* All acute toxicities caused by prior anti-tumor therapy or surgery must have resolved to Grade 0-1 (according to NCI CTCAE v5.0) or to the level specified in the inclusion\u002Fexclusion criteria. Alopecia, fatigue, and hearing loss, or other toxicities considered by the investigator not to pose a safety risk to the subject, are excluded.\n* Adequate organ function (laboratory tests within 7 days prior to treatment):\n\n  * Hematology (No blood transfusion, G-CSF use, or drug correction within 14 days prior to screening):\n  * White blood cell count (WBC) ≥ 3,000\u002Fmm³ (3.0 × 10⁹\u002FL);\n  * Absolute neutrophil count (ANC) ≥ 1,500\u002Fmm³ (1.5 × 10⁹\u002FL);\n  * Platelet count (PLT) ≥ 100,000\u002Fmm³ (100 × 10⁹\u002FL);\n  * Hemoglobin (Hb) ≥ 9.0 g\u002FdL (90 g\u002FL).\n* Biochemistry (No albumin transfusion within 14 days prior to screening):\n\n  * Albumin ≥ 3.0 g\u002FdL (30 g\u002FL);\n  * Creatinine ≤ 1.5 × Upper Limit of Normal (ULN) or Creatinine Clearance ≥ 50 ml\u002Fmin (calculated using the Cockcroft-Gault formula);\n  * Total Bilirubin (BIL) ≤ 1.5 × ULN;\n  * Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) levels ≤ 2.5 × ULN; for patients with liver metastases, ≤ 5 × ULN.\n* Coagulation: International Normalized Ratio (INR) ≤ 1.5, Prothrombin Time (PT), and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.\n* Urine: Urine protein \\\u003C 2+; if urine protein is ≥ 2+, 24-hour urine protein quantification must be ≤ 1g.\n* Life expectancy ≥ 3 months.\n* Women of childbearing potential must undergo a serum or urine pregnancy test within 7 days before starting treatment, with a negative result, and must not be lactating. All enrolled patients must use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n* Known squamous cell carcinoma, undifferentiated carcinoma, other histological types of gastric cancer, or mixed gastric cancer containing other histological types.\n* Active malignant tumors within the past 2 years, other than the tumor under study. Exceptions include subjects with locally curable cancers (that have been cured), such as basal or squamous cell skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix or breast.\n* Participation in a study of an investigational drug or receipt of investigational treatment or use of an investigational device within 4 weeks prior to the first dose.\n* Enrollment in another clinical study, unless it is an observational, non-interventional clinical study or the follow-up period of an interventional study (defined as \\>4 weeks since the last dose of the previous clinical study or \\>5 half-lives of the study drug).\n* Untreated Central Nervous System (CNS) metastases, or uncontrolled or symptomatic active CNS metastases. Patients with fully treated CNS metastases may be enrolled if neurological symptoms have returned to baseline levels at least 4 weeks prior to enrollment (excluding residual signs or symptoms related to CNS treatment). Additionally, subjects must have discontinued corticosteroids or be on a stable or tapering dose of prednisone ≤ 10 mg\u002Fd (or equivalent dose of other corticosteroids) for at least 4 weeks prior to enrollment.\n* Pleural effusion or ascites that remains uncontrolled despite puncture and drainage within 14 days prior to enrollment; symptomatic or moderate-to-large pericardial effusion.\n* Weight loss of more than 20% within 2 months prior to enrollment.\n* Received the following treatments or medications prior to enrollment:\n\n  * Major surgery within 28 days prior to enrollment (tissue biopsy for diagnosis and PICC\u002Fport implantation are allowed).\n  * Use of immunosuppressive drugs within 14 days prior to enrollment, excluding nasal\u002Finhaled corticosteroids or physiological doses of systemic steroids (i.e., ≤ 10 mg\u002Fd prednisone or equivalent).\n  * Vaccination with live attenuated vaccines within 28 days prior to enrollment or planned during the study period and within 60 days after the end of study drug treatment.\n  * Local anti-tumor therapy (e.g., radiotherapy or tumor embolization) within 28 days prior to enrollment.\n* Diagnosed with any other malignant tumor within 5 years prior to entering the study, except for cured cutaneous basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma amenable to local treatment.\n* Presence of any active, known, or suspected autoimmune disease. Subjects in a stable state not requiring systemic immunosuppressive therapy are allowed, such as Type I diabetes, hypothyroidism requiring only hormone replacement therapy, and skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia).\n* Prior treatment with any anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody, or any other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.\n* Significant clinical bleeding symptoms or definite bleeding tendency within 3 months prior to enrollment; gastrointestinal perforation and\u002For fistula within 6 months prior to enrollment; arterial\u002Fvenous thromboembolic events within 6 months prior to enrollment, such as cerebrovascular accident (including TIA, cerebral infarction), deep vein thrombosis, and pulmonary embolism (except for those with gastric cancer bleeding\u002Fperforation where symptoms disappeared after surgical resection).\n* Major vascular disease within 6 months before the start of study treatment (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis).\n* Severe, unhealed, or dehisced wounds, active ulcers, or untreated fractures.\n* Presence of \\> Grade 1 peripheral neuropathy.\n* History of intestinal obstruction and\u002For clinical signs or symptoms of gastrointestinal obstruction within 6 months before starting study treatment, including incomplete obstruction related to the underlying disease or requiring routine parenteral hydration, parenteral nutrition, or tube feeding. Patients with incomplete obstruction\u002Fobstruction syndrome at initial diagnosis who have symptom relief after definitive (surgical) treatment may be enrolled.\n* Interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, acute pneumonia, etc.).\n* Known history of active tuberculosis.\n* Known allergy to the study drug or any of its excipients; or history of severe allergic reactions to other monoclonal antibodies.\n* HIV infection or known Acquired Immunodeficiency Syndrome (AIDS); untreated active hepatitis (Hepatitis B defined as HBV-DNA ≥ 500 IU\u002Fml; Hepatitis C defined as anti-HCV positive and HCV RNA above the lower limit of detection) or co-infection with Hepatitis B and C.\n* Poorly controlled clinical cardiac symptoms or diseases, such as: (1) NYHA Class II or higher cardiac insufficiency or LVEF \\\u003C 50% on echocardiography; (2) Severe\u002Funstable angina; (3) Myocardial infarction within 12 months prior to enrollment; (4) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; (5) Symptomatic congestive heart failure; (6) QTc \\> 480 ms.\n* Systemic use of antibiotics ≥ 7 days within 4 weeks prior to enrollment, or unexplained fever \\> 38.5°C during screening\u002Fbefore first dose (fever due to tumor causes is allowed per investigator judgment).\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Participation in any other drug clinical study within 4 weeks or 5 half-lives prior to enrollment.\n* Known history of psychotropic drug abuse or drug addiction.\n* Presence of other severe physical or mental illnesses or laboratory abnormalities that may increase the risk of participation, interfere with study results, or render the patient unsuitable for the study in the opinion of the investigator.",{"count":549,"type":23},32,[26],"The goal of this Phase II clinical trial is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) combined with SOX chemotherapy (S-1 plus Oxaliplatin) in patients with previously untreated advanced or metastatic gastric cancer or gastroesophageal junction cancer.\n\nThe main questions it aims to answer are:\n\n1、What is the objective response rate (ORR) of the combination of QL1706 and SOX chemotherapy? 2、What are the safety and tolerability of this combination therapy? Participants will：\n\n1. Receive Iparomlimab and Tuvonralimab (QL1706) via intravenous infusion every 3 weeks.\n2. Receive SOX chemotherapy (Oxaliplatin via intravenous infusion on Day 1 and S-1 orally twice daily for 14 days) every 3 weeks for up to 6 cycles.\n3. Continue maintenance therapy with QL1706 combined with S-1 after 6 cycles until disease progression or unacceptable toxicity.\n4. Undergo tumor imaging assessments (CT or MRI) every 6 weeks for the first 24 weeks, and then every 9 weeks thereafter to monitor the disease.",[553,554,555,556],"Gastric Cancer (GC)","Gastroesophageal Junction Cancer","Advanced Gastric Cancer","Metastatic Gastric Cancer",[558,559,560,561,562,563,362],"Iparomlimab and Tuvonralimab","QL1706","Advanced or Metastatic Gastric Cancer","PD-1\u002FCTLA-4 Bispecific Antibody","Immunotherapy","Chemotherapy Combination","2026-01-02",{"date":566,"type":43},"2026-01-06",{"date":568,"type":43},"2025-11-04",{"date":296,"type":23},{"name":49,"class":50},{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":80,"sex":18,"minAge":577,"maxAge":356,"enrollmentInfo":578,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":4},"100618475","the-application-of-extracellular-vesicle-detection-in-gastric-juice-based-on-metamaterial-sensing-in-the-diagnosis-of-gastric-cancer-and-related-diseases-100618475","NCT07332104","The Application of Extracellular Vesicle Detection in Gastric Juice Based on Metamaterial Sensing in the Diagnosis of Gastric Cancer and Related Diseases","Inclusion Criteria:\n\n* Patients underwent gastroscopy and treatment at the Endoscopy Center of Beijing Friendship Hospital, Capital Medical University, and received pathological biopsy.\n* Previous gastroscopy suggested the possibility of lesions.\n* No previous history of gastrointestinal cancer.\n\nExclusion Criteria:\n\n* Patients could not cooperate with the examination or had contraindications to endoscopy.\n* Previous history of gastrointestinal tumors, gastrointestinal surgery, physical and chemical injuries of the gastrointestinal tract.\n* Severe bile reflux.\n* Take simethicone and other defoaming agents before examination.\n* Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs.","40 Years",{"count":579,"type":23},100,"After obtaining informed consent from the patients, all the medical history and treatment records of the patients who underwent gastroscopy since the onset of the disease, as well as gastric fluid samples, including laboratory and imaging data, were collected and recorded. The medical history and treatment records and gastric fluid samples were analyzed.",[553,582],"Gastric Cancer (Diagnosis)",[364,584],"Extracellular vesicles","2025-12-28",{"date":512,"type":43},{"date":588,"type":23},"2025-12-15",{"date":590,"type":23},"2026-12-15",{"name":49,"class":50},{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":599,"enrollmentInfo":600,"targetDuration":4,"studyType":24,"phases":602,"briefSummary":603,"conditions":604,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":613,"locationsCount":540},"100612325","tlsa-versus-tbsa-surgical-approach-for-hiatal-hernia-with-gastroesophageal-reflux-disease-100612325","NCT07252115","TLSA Versus TBSA Surgical Approach for Hiatal Hernia With Gastroesophageal Reflux Disease","Multicenter Randomized Clinical Trial on the Efficacy and Safety of the Total Left-side Surgical Approach (TLSA) Versus the Traditional Bilateral Surgical Approach (TBSA) for Hiatal Hernia With Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n* Patients aged 18 to 85 years.\n* Confirmed diagnosis of hiatal hernia (type I to IV).\n* Diagnosis of refractory GERD, defined as persistent symptoms despite receiving 40 mg daily omeprazole for 8-12 weeks.\n* GERD confirmed by either:\n* Increased esophageal acid exposure time (AET) on 24-hour pH monitoring, and\u002For\n* Endoscopic evidence of esophagitis.\n* Hiatal hernia diagnosis verified by both abdominal CT and gastroscopy.\n\nExclusion Criteria:\n\n* Presence of GERD without a hiatal hernia.\n* Esophageal motility disorder.\n* History of esophageal or other upper abdominal surgery.","85 Years",{"count":601,"type":23},143,[60],"Gastroesophageal reflux disease (GERD), characterized by pathological reflux of gastric contents, affects 10%-20% of the global population with Western predominance and escalating incidence over recent decades. Anatomical and functional abnormalities of the esophagogastric junction (EGJ) such as hiatal hernia (HH) is one of the major pathophysiological mechanisms. GERD elevates risks for Barrett esophagus, esophageal adenocarcinoma and interstitial pulmonary fibrosis, while characteristic symptoms including reflux and heartburn substantially impair quality of life (QoL). Proton pump inhibitors (PPIs) are used to alleviate symptoms and prevent reflux-related esophageal mucosal damage, but may cause long-term adverse effects.\n\nAnti-reflux surgery (ARS) is a well-established therapeutic option for patients with anatomical abnormalities, chronic PPI-refractory symptoms or unwilling to take lifelong PPIs. It provides comparable or potentially superior efficacy to PPIs, especially in reconstructing anatomical structures and addressing EGJ functional deficiencies. Maximize patients' QoL while minimizing side effects is priority for ARS. Despite advancements in surgical techniques, ARS remains invasive and is associated with inherent mechanical complications, including dysphagia and potential vagus nerve injury. A growing consensus recognizes that hepatic vagus nerve injury, occurring in a significant proportion of patients following ARS, potentially contributes to postoperative dysfunctions such as delayed gastric emptying, impaired reflux control, dyspeptic symptoms, cholelithiasis, ultimately diminishing QoL.\n\nAlthough the traditional bilateral surgical approach (TBSA) is widely used, its requisite dissection of the lesser omentum invariably injures or severs the hepatic branch of the vagus nerve. The hepatic branch of the vagus arises from the anterior trunk and predominantly innervates the gastric antrum, pylorus, proximal duodenum and biliary tract. Functionally, it mediates a spectrum of vital physiological process including hepato-gastric reflexes that facilitate gastric motility via osmotic sensing, as well as glucose-sensitive reflexes that inhibit gastric motility and delay gastric emptying. Furthermore, hepatic branch is involved in food intake and metabolic homeostasis, and it exerts parasympathetic control over the coordinated contraction of the gallbladder and sphincter of Oddi. However, the functional preservation of the hepatic branch of the vagus nerve during ARS remains poorly understood, with limited clinical evidence and absent robust guidelines.\n\nBased on our preliminary findings, we initiated a long-term evaluation of the total left-side approach (TLSA), a nerve-sparing strategy that preserves the lesser omentum and hepatogastric ligament to safeguard the hepatic branch of the vagus nerve, with the aim of enhancing postoperative QoL.",[605,606],"Hernia, Hiatal","GERD (Gastroesophageal Reflux Disease)","2025-11-25",{"date":609,"type":43},"2025-11-26",{"date":611,"type":43},"2024-04-04",{"date":126,"type":23},{"name":49,"class":50},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":622,"targetDuration":623,"studyType":83,"phases":4,"briefSummary":624,"conditions":625,"keywords":627,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":637,"locationsCount":638},"100443890","a-prognostic-model-for-drug-induced-liver-injury-in-china-100443890","NCT05060289","A Prognostic Model for Drug-induced Liver Injury in China","A Prognostic Model for Drug-induced Liver Injury in China : A Multi-center, Prospective Cohort Study","DILI-PM","Inclusion Criteria:\n\n1. RUCAM ≥6 and met one of the following biochemical conditions: (1) ALT≥5 ULN, (2) or ALP ≥2 ULN, (3) or ALT≥3 ULN and TBil≥2 ULN.\n2. RUCAM between 3-5, five experienced hepatologists in leading site evaluate and vote the diagnosis of DILI, the case would be enrolled if only ≥4 out of 5 hepatologists agree with the diagnosis.\n3. Onset to enrollment ≤3 months.\n\nExclusion Criteria:\n\n1. Hepatotropic viral infection: hepatitis A, B, C, D and E.\n2. Non-hepatotropic viral infection: cytomegalovirus (CMV) and Epstein-Barr virus (EBV), etc.\n3. Hypoxic ischemic hepatitis and congestive liver disease.\n4. Alcohol consumption: male \\>40g\u002Fd, female \\>20g\u002Fd, and ≥5 years.\n5. Biliary obstruction, primary biliary cholangitis; primary sclerosing cholangitis.\n6. Autoimmune hepatitis: International Autoimmune Hepatitis Group (IAHG) simplified score ≥6 or complicated score ≥10, or differentiation from autoimmune hepatitis is impossible during enrollment.\n7. Parasitic infection.\n8. Sepsis.\n9. Previous liver transplantation or bone marrow transplantation.\n10. Pregnancy or lactation.\n11. Genetic and metabolic liver diseases.",{"count":136,"type":23},"2 Years","A prospective, multi-center, non-interventional cohort study is going to conduct to explore the clinical characteristics, culprit drug(s) or herb(s), outcomes and risk factors of Drug-induced liver injury (DILI) in China and screen novel serum markers.\n\nA prognostic model incorporating with the novel serum marker(s) for DILI would be established and validated to imporve the prognosis of patients in China .",[626],"Drug-induced Liver Injury",[628,629,630],"prognostic model(s)","biomarker(s)","endpoint event(s)","2025-09-17",{"date":633,"type":43},"2025-09-22",{"date":635,"type":43},"2022-05-25",{"date":203,"type":23},{"name":49,"class":50},13,""]